Sangamo Therapeutics and Biogen Announce Gene-Therapy Deal, Stock up 39%
Sangamo Therapeutics (NASDAQ: SGMO) announced after the bell on Thursday that it signed a partnership with Biogen (NASDAQ: BIIB) to develop a number of gene-editing treatments. The scope of the agreement would focus on neurological and neuromuscular conditions, with an initial focus on treating Alzheimer's and Parkinson's diseases.
Sangamo currently has 17 separate preclinical or early-stage clinical projects going on at the moment. One of these, ST-501, targets a class of neurodegenerative disorders known as tauopathies, which include conditions such as Parkinson's disease. Another candidate Sangamo is working on, ST-502, treats another class of neurodegenerative disorders known as synucleinopathies, which includes Alzheimer's disease.
Image source: Getty Images.
Source Fool.com
